Literature DB >> 25400094

Subtyping of breast cancer using reverse phase protein arrays.

Johanna Sonntag1, Kerstin Schlüter, Stephan Bernhardt, Ulrike Korf.   

Abstract

Reverse phase protein arrays (RPPAs) present a robust and sensitive high capacity platform for targeted proteomics that relies on highly specific antibodies to obtain a quantitative readout regarding phosphorylation state and abundance of proteins of interest. This review summarizes the current state of RPPA-based proteomic profiling of breast cancer in the context of existing preanalytical strategies and sample preparation protocols. RPPA-based subtypes identified so far are compared to those obtained by other approaches such as immunohistochemistry, genomics and transcriptomics. Special attention is given to discussing the potential of RPPA for biomarker discovery and biomarker validation.

Entities:  

Keywords:  HER2; RPPA; breast cancer; hormone receptor; molecular subtyping; reverse phase protein array; signaling pathways

Mesh:

Substances:

Year:  2014        PMID: 25400094     DOI: 10.1586/14789450.2014.971113

Source DB:  PubMed          Journal:  Expert Rev Proteomics        ISSN: 1478-9450            Impact factor:   3.940


  4 in total

1.  Disentangling ERBB Signaling in Breast Cancer Subtypes-A Model-Based Analysis.

Authors:  Svenja Kemmer; Mireia Berdiel-Acer; Eileen Reinz; Johanna Sonntag; Nooraldeen Tarade; Stephan Bernhardt; Mirjam Fehling-Kaschek; Max Hasmann; Ulrike Korf; Stefan Wiemann; Jens Timmer
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

2.  Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.

Authors:  Özge Saatci; Simone Borgoni; Özge Akbulut; Selvi Durmuş; Umar Raza; Erol Eyüpoğlu; Can Alkan; Aytekin Akyol; Özgür Kütük; Stefan Wiemann; Özgür Şahin
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

Review 3.  Analysis of Reverse Phase Protein Array Data: From Experimental Design towards Targeted Biomarker Discovery.

Authors:  Astrid Wachter; Stephan Bernhardt; Tim Beissbarth; Ulrike Korf
Journal:  Microarrays (Basel)       Date:  2015-11-03

4.  Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening.

Authors:  Erta Kalanxhi; Helga Helseth Hektoen; Sebastian Meltzer; Svein Dueland; Kjersti Flatmark; Anne Hansen Ree
Journal:  BMC Cancer       Date:  2016-07-26       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.